E! 2569 Remwave
| Reference number | |
| Coordinator | CSW Therapeutics AB |
| Funding from Vinnova | SEK 4 053 255 |
| Project duration | March 2023 - March 2026 |
| Status | Ongoing |
| Venture | Eurostars |
Purpose and goal
This project aims to develop a novel technology for cardiac shockwave therapy and remote myocardial function monitoring, using non-invasive sensor technologies to enable proactive treatments. The device developed through this project, Remwave, will enable cardiac shockwave therapy (CSWT) for the treatment of refractory angina a chronic condition characterized by sever chest pain caused by coronary artery disease (CAD). Remwave device is designed to be used by the patient in home environment and will be a cost- and resource-effective alternative to today’s existing solutions.
Expected effects and result
The final results of the project is the Remwave device, which is a cardiac shock wave treatment device that is administered by the patient in a home environment. The product provides: Personalized and adaptive treatment of coronary artery disease Self-administered & cost-effective Fewer side effects than conventional shock wave therapy due to lower intensity and personalized therapy Continuous monitoring of heart health
Planned approach and implementation
The project is divided into five work packages, focusing on different parts of product development as well as regulatory aspects that are important for successful creation and clinical implementation. Work package 1: is about hardware development and design Work package 2: AI model development which contributes to both monitoring and treatment. Work package 3: deals with data collection and animal clinical studies of the device Work package 4 & 5: We focus on medical device testing requirements and the regulatory aspects of product development.